Nathalie Zeitouni, MD, CM, FRCPC, FAAD

NP Schollenberger addresses the particularly challenging and understudied population of immunocompromised patients with advanced CSCC.

Both panelists describe multidisciplinary care coordination models.

Dr. Hamid presents an 86-year-old retired construction worker with diabetes, hypertension, and prior basal cell carcinoma, now with a 2.8 cm facial CSCC lesion and imaging-confirmed pulmonary metastases.

Dr. Zeitouni compares immune-mediated adverse event rates across checkpoint inhibitor agents in advanced CSCC.

Dr. Hamid presents a 71-year-old male smoker with coronary artery disease and a 3.5 cm cervical CSCC lesion that has recurred after multiple surgical resections and adjuvant radiation therapy.

NP Schollenberger addresses how she interprets and communicates efficacy data to patients.

Experts unpack advanced cutaneous squamous cell carcinoma risks, comorbidities, and PD-1/PD-L1 immunotherapy strategies for unresectable disease.

Experts unpack unresectable cutaneous squamous cell carcinoma, weighing PD-1/PD-L1 immunotherapy benefits and risks in older, comorbid patients.